Sökning: "patient-derived models"
Visar resultat 16 - 20 av 43 avhandlingar innehållade orden patient-derived models.
16. On the nature of mixed neurodegenerative amyloidopathies
Sammanfattning : Alzheimer's disease (AD) and Parkinson's disease (PD) are the most common neurodegenerative diseases in the world. It has been possible to identify common denominators for AD and PD, including aggregation of the amyloid proteins amyloid-beta (Aβ) and alpha-synuclein (α-syn). LÄS MER
17. Modeling glioblastoma growth patterns and their mechanistic origins
Sammanfattning : Glioblastoma (GBM) is the most common and aggressive primary brain cancer. GBM cells migrate away from the primary lesion and invade healthy brain tissue. The invading cells escape surgical resection, radiotherapy and develop resistance to chemotherapy. Consequently, despite treatment, recurrence is inevitable, and survival is only 14 months. LÄS MER
18. Complement mediated synapse elimination in schizophrenia
Sammanfattning : Schizophrenia (SCZ) is a devastating psychiatric disorder with a typically age of onset in late adolescence. The heritability is estimated to be in between 60-80% and large-scale genome-wide studies have revealed a prominent polygenic component to SCZ risk and identified more than three-hundred common risk variants. LÄS MER
19. Induced pluripotent stem cell (iPSC) modelling for the identification of mechanisms behind neurodevelopmental disorders
Sammanfattning : Human induced pluripotent stem cells (iPSCs) have opened new possibilities to recapitulate disease mechanisms and to model disorders in vitro. In the studies presented here, iPSCs were established to model neural differentiation in Down syndrome (DS), caused by trisomy for chromosome 21 (T21); Dravet syndrome (DRS), caused by variants in the SCN1A gene; and an ataxia syndrome, caused by a variant in the NFASC gene. LÄS MER
20. Molecular subclassification, stem cell markers and growth regulatory pathways in gliomas
Sammanfattning : Glioblastoma is the most common and aggressive primary brain tumor in adults. Median survival is no more than 15 months, even with combined treatment regimens. The lack of accurate pre-clinical model systems has limited the development of new treatment options for this deadly disease. LÄS MER